UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

Journal of clinical oncology, 2002-11, Vol.20 (21), p.4292-4302

2002

Volltextzugriff (PDF)

Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: Results of a prospective gynecological ultrasound substudy

Gynecologic oncology, 2010-12, Vol.119 (3), p.500-505

2010

Volltextzugriff (PDF)

The effect of exemestane or tamoxifen on markers of bone turnover: Results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial

Breast (Edinburgh), 2009-06, Vol.18 (3), p.159-164

2009

Volltextzugriff (PDF)

Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy

Annals of oncology, 2009-07, Vol.20 (7), p.1203-1209

2009

Volltextzugriff (PDF)

Multicenter phase II study of oral capecitabine (Xeloda“) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy

Annals of oncology, 2003-08, Vol.14 (8), p.1227-1233

2003

Volltextzugriff (PDF)

Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM

Annals of oncology, 2012-10, Vol.23 (10), p.2566-2572

2012

Volltextzugriff (PDF)

Endometrial safety of cross-over treatment with tamoxifen followed by exemestane

European journal of cancer supplements, 2008, Vol.6 (7), p.198-198

2008

Volltextzugriff (PDF)

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

Annals of oncology, 2004-03, Vol.15 (3), p.440-449

2004

Volltextzugriff (PDF)

Histologic and immunohistochemical analysis of tissue response to adenovirus‐mediated herpes simplex thymidine kinase gene therapy of ovarian cancer

International journal of gynecological cancer, 2002-01, Vol.12 (1), p.66-73

2002

Volltextzugriff (PDF)

Adenovirus-mediated Thymidine Kinase Gene Therapy Induces Apoptosis in Human Epithelial Ovarian Cancer Cells and Damages PARP-1

In vivo (Athens), 2009-01, Vol.23 (1), p.77

Kieback, D G

2009

Volltextzugriff (PDF)

Adenovirus-mediated Thymidine Kinase Gene Therapy and Coxsackie Adenovirus Receptor Expression in Ovarian Cancer Cells

Cancer genomics & proteomics, 2008-11, Vol.5 (6), p.311

Kieback, D G

2008

Volltextzugriff (PDF)

Persistent Adenovirus-mediated Thymidine Kinase Gene Expression in Ovarian Cancer Cells Increases Cell Killing Efficacy Over Time

Anticancer research, 2008-09, Vol.28 (5A), p.2569-2575

2008

Volltextzugriff (PDF)

Adenovirus-Mediated Thymidine Kinase Gene Therapy in Combination with Topotecan for Patients with Recurrent Ovarian Cancer: 2.5-Year Follow-Up

Gynecologic oncology, 2001-12, Vol.83 (3), p.549-554

2001

Volltextzugriff (PDF)

Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study

Oncology research and treatment, 2001-06, Vol.24 (3), p.256-260

2001

Volltextzugriff (PDF)

Adnexal masses in pregnancy

Oncology research and treatment, 2003-04, Vol.26 (2), p.167-172

2003

Volltextzugriff (PDF)

Cloning, expression analysis and chromosomal localization of the human nuclear receptor gene GCNF

FEBS letters, 1998-03, Vol.424 (1), p.73-78

1998

Volltextzugriff (PDF)

Combination of adenovirus-mediated thymidine kinase gene therapy with cytotoxic chemotherapy in bladder cancer in vitro

Urologic oncology, 2003-05, Vol.21 (3), p.197-205

2003

Volltextzugriff (PDF)

p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer

The Lancet (British edition), 1995-04, Vol.345 (8955), p.994-994

1995

Volltextzugriff (PDF)

Aggressive management of recurrent ovarian cancer--the challenge of individualizing cancer therapy illustrated by a case report

Oncology research and treatment, 2004-01, Vol.27 (4), p.393-397

2004

Volltextzugriff (PDF)

Molecular mechanisms in signal transduction: new targets for the therapy of gynecologic malignancies

Oncology research and treatment, 2002-06, Vol.25 (3), p.240-247

2002

Volltextzugriff (PDF)

Fetal monitoring by a novel non-invasive device for measuring oxygen saturation

International journal of gynecology and obstetrics, 2000, Vol.70 (S3), p.C34-C34

2000

Volltextzugriff (PDF)

Chicken Ovalbumin Upstream Promoter Transcription Factor (COUP-TF): An Orphan Steroid Receptor with a Specific Pattern of Differential Expression in Human Ovarian Cancer Cell Lines

Gynecologic oncology, 1993-11, Vol.51 (2), p.167-170

1993

Volltextzugriff (PDF)

In VivoGene Therapy of Ovarian Cancer by Adenovirus-Mediated Thymidine Kinase Gene Transduction and Ganciclovir Administration

Gynecologic oncology, 1996-05, Vol.61 (2), p.175-179

1996

Volltextzugriff (PDF)

p53 Gain-of-function mutation in codon 175 is a rare event in human breast cancer

Human molecular genetics, 1993-09, Vol.2 (9), p.1501-1502

1993

Volltextzugriff (PDF)

The prediction of survival in serous ovarian cancer by the composition-adjusted receptor level (CARL) for estrogen and HER-2/ neu oncogene expression

Gynecologic oncology, 1992-04, Vol.45 (1), p.86-86

1992

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Gynecologic Oncology
(5)
Annals Of Oncology
(4)
Oncology Research And Treatment
(4)
Onkologie
(4)
Prostaglandins
(2)
Anticancer Research
(1)
Breast
(1)
Cancer Genomics & Proteomics
(1)
European Journal Of Cancer Supplements
(1)
Febs Letters
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: Results of a prospective gynecological ultrasound substudy

The effect of exemestane or tamoxifen on markers of bone turnover: Results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial

Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy

Multicenter phase II study of oral capecitabine (Xeloda“) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy

Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM

Endometrial safety of cross-over treatment with tamoxifen followed by exemestane

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

Histologic and immunohistochemical analysis of tissue response to adenovirus‐mediated herpes simplex thymidine kinase gene therapy of ovarian cancer

Adenovirus-mediated Thymidine Kinase Gene Therapy Induces Apoptosis in Human Epithelial Ovarian Cancer Cells and Damages PARP-1

Adenovirus-mediated Thymidine Kinase Gene Therapy and Coxsackie Adenovirus Receptor Expression in Ovarian Cancer Cells

Persistent Adenovirus-mediated Thymidine Kinase Gene Expression in Ovarian Cancer Cells Increases Cell Killing Efficacy Over Time

Adenovirus-Mediated Thymidine Kinase Gene Therapy in Combination with Topotecan for Patients with Recurrent Ovarian Cancer: 2.5-Year Follow-Up

Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study

Adnexal masses in pregnancy

Cloning, expression analysis and chromosomal localization of the human nuclear receptor gene GCNF

Combination of adenovirus-mediated thymidine kinase gene therapy with cytotoxic chemotherapy in bladder cancer in vitro

p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer

Aggressive management of recurrent ovarian cancer--the challenge of individualizing cancer therapy illustrated by a case report

Molecular mechanisms in signal transduction: new targets for the therapy of gynecologic malignancies

Fetal monitoring by a novel non-invasive device for measuring oxygen saturation

Chicken Ovalbumin Upstream Promoter Transcription Factor (COUP-TF): An Orphan Steroid Receptor with a Specific Pattern of Differential Expression in Human Ovarian Cancer Cell Lines

In VivoGene Therapy of Ovarian Cancer by Adenovirus-Mediated Thymidine Kinase Gene Transduction and Ganciclovir Administration

p53 Gain-of-function mutation in codon 175 is a rare event in human breast cancer

The prediction of survival in serous ovarian cancer by the composition-adjusted receptor level (CARL) for estrogen and HER-2/ neu oncogene expression

Suchergebnisse filtern